FDA Brief

Warning letters Drugs

FDA warning letter to

Marshalls Traditional Healthcare CC

High riskIssued Feb 10, 2025Posted Feb 18, 2025Center for Drug Evaluation and Research (CDER)

Marshalls Traditional Healthcare, an OTC drug maker in South Africa, lacked finished-product release testing and process validation.

What happened

FDA inspected the Germiston facility from September 19 to 23, 2024, and found significant current good manufacturing practice (CGMP) violations for finished pharmaceuticals. The letter says the firm released OTC drug batches without adequate finished-product testing for active ingredient identity and strength and for harmful microorganisms, and it cites inadequate process validation and inadequate control of a manufacturing system. FDA reviewed the firm's October 11, 2024, response and found it inadequate.

What FDA found

  1. The firm did not test each finished drug batch for identity and strength of the active ingredient and for harmful microorganisms before release.

    21 CFR 211.165(a) and 211.165(b)
  2. The firm did not have adequate written production and process control procedures and did not follow all of its written procedures.

    21 CFR 211.100(a) and 211.100(b)
  3. The firm did not validate its manufacturing processes with operating parameters, hold times, acceptance criteria, and adequate sampling instructions.

    21 CFR 211.100(a) and 211.100(b)
  4. The firm did not ensure that a manufacturing system used to produce a drug component was suitable or adequately monitored for chemical and microbial attributes.

    21 CFR 211.100(a) and 211.100(b)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with its corrective actions and plans to prevent recurrence; the letter also requests detailed remediation plans, a risk assessment for affected U.S. lots, and clarification of whether it will resume U.S. drug manufacturing. Before resuming, the firm must notify FDA and provide a summary of completed corrective and preventive actions.

Who should pay attention

  • U.S. distributors and retailers selling this firm's OTC drugs
  • companies using Marshalls Traditional Healthcare as a contract drug manufacturer
  • importers of South African drug or cosmetic products for the U.S. market

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. TSP Solutions Pte. Ltd.

    FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

    High risk
  3. Eurofins SF Analytical Laboratories, Inc.

    FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.

    High risk
  4. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk